Meloxicam
- Generic Name
- Meloxicam
- Brand Names
- Anjeso, Mobic, Qmiiz, Vivlodex
- Drug Type
- Small Molecule
- Chemical Formula
- C14H13N3O4S2
- CAS Number
- 71125-38-7
- Unique Ingredient Identifier
- VG2QF83CGL
- Background
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intr...
- Indication
Meloxicam is indicated for the symptomatic treatment of arthritis and osteoarthritis. In addition, it is indicated for the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above. Off-label uses include the treatment of dental or post-surgical pain. In addition to the above, meloxicam has also been...
- Associated Conditions
- Dental Pain, Neuropathic Pain, Osteoarthritis (OA), Pain, Inflammatory, Pauciarticular juvenile rheumatoid arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Postoperative pain, Rheumatoid Arthritis
- Associated Therapies
- -
A Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the Knee
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02183116
Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1309
- Registration Number
- NCT02183064
Observational Study of Meloxicam in Any Labeled Indication
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13039
- Registration Number
- NCT02182739
Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome
- Conditions
- Interventions
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 9984
- Registration Number
- NCT02180516
A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Sherif S. Farag
- Target Recruit Count
- 38
- Registration Number
- NCT02078102
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Meloxicam vs Placebo for Mobilization
- Conditions
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT02003625
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee
- Conditions
- Interventions
- First Posted Date
- 2011-09-08
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 408
- Registration Number
- NCT01430559
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳Anhui Province Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Shantou Medical Collage, Shantou City, Guangdong, China
Study of a COX-2 Inhibitor for Prevention of Ovulation
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- Instituto Chileno de Medicina Reproductiva
- Target Recruit Count
- 56
- Registration Number
- NCT01346137
- Locations
- 🇨🇱
Instituto Chileno de Medicina Reproductiva (ICMER), Santiago, Chile
Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2010-07-13
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 28
- Registration Number
- NCT01161134
- Locations
- 🇨🇦
Allied Research International Inc., Mississauga, Ontario, Canada
Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2010-07-13
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 28
- Registration Number
- NCT01161147
- Locations
- 🇨🇦
Allied Research International Inc., Mississauga, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.